FLUXID
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Sep 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FLUXID by UCB Pharma is clinical pharmacology in adults gi effects famotidine is a competitive inhibitor of histamine h 2 -receptors. First approved in 2004.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLUXID is an orally disintegrating tablet formulation of famotidine, a histamine H2-receptor antagonist that inhibits gastric acid secretion. It is indicated for the treatment of duodenal ulcers and acid-related gastrointestinal conditions. Famotidine works by competitively blocking H2 receptors to reduce both the concentration and volume of gastric acid, with onset of action within one hour and peak effect within 1–3 hours.
LOE Approaching
Product is in late-stage commercialization with approaching loss of exclusivity; team size and hiring likely stable to declining as transition planning begins.
Mechanism of Action
CLINICAL PHARMACOLOGY IN ADULTS GI Effects Famotidine is a competitive inhibitor of histamine H 2 -receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by…
Worked on FLUXID at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.